pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

4,900 catalysts · 4,686 phase readout · 2,347 8k filing · 285 earnings · 213 pdufa · 172 phase 2 completion · 73 phase 1 completion

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-07-20: 0 catalysts2026-07-21: 0 catalysts2026-07-22: 14 catalysts2026-07-23: 2 catalysts2026-07-24: 1 catalyst2026-07-25: 0 catalysts2026-07-26: 0 catalysts2026-07-27: 2 catalysts2026-07-28: 4 catalysts2026-07-29: 12 catalysts2026-07-30: 12 catalysts2026-07-31: 3 catalysts2026-08-01: 0 catalysts2026-08-02: 0 catalysts2026-08-03: 4 catalysts2026-08-04: 12 catalysts2026-08-05: 14 catalysts2026-08-06: 10 catalysts2026-08-07: 1 catalyst2026-08-08: 0 catalysts2026-08-09: 0 catalysts2026-08-10: 1 catalyst2026-08-11: 1 catalyst2026-08-12: 1 catalyst2026-08-13: 0 catalysts2026-08-14: 0 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 0 catalysts2026-08-18: 1 catalyst2026-08-19: 0 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 0 catalysts2026-08-27: 0 catalysts2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 0 catalysts2026-09-02: 0 catalysts2026-09-03: 0 catalysts2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 0 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 0 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 0 catalysts2026-10-14: 0 catalysts2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts
view
agendamonth
show past →
sort
soonestlatesttypesponsoralpha
type: adcom×type: pdufa×type: phase readout×clear all
type
  • phase readout4,686
  • 8k filing2,347
  • earnings285
  • pdufa213
  • phase 2 completion172
  • phase 1 completion73
phase 2 initiation
62
  • phase 1 initiation40
  • phase 1 2 completion35
  • phase 0 trial completion23
  • therapy area
    • Dermatology1
    • Infectious Disease1

    Date TBD

    50
    ›NOT_YET_RECRUITINGphase readoutNCT07590193: A Trial Evaluating AMG 127 in Healthy Participants and Participants With Type 2 Diabetes Mellitus

    Sponsor: Amgen. Phase: PHASE1. Conditions: Diabetes Mellitus, Type 2

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT04211714: Study to Evaluate of EXG34217 in Patients With Telomere Biology Disorders With Bone Marrow Failure

    Sponsor: Elixirgen Therapeutics, Inc.. Phase: PHASE1. Conditions: Telomere Shortening, Bone Marrow Failure

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT07400016: Efficacy of Superoxide Dismutase Spray in Preventing Radiation Dermatitis in Patients With Head and Neck Cancer .

    Sponsor: West China Hospital. Phase: NA. Conditions: Radiation Dermatitis

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT04889716: CAR-T Followed by Bispecific Antibodies

    Sponsor: Abramson Cancer Center at Penn Medicine. Phase: PHASE2. Conditions: Large B-cell Lymphoma, DLBCL - Diffuse Large B Cell Lymphoma

    full page →ctgov ↗
    ›TERMINATEDphase readoutNCT04347616: Natural Killer-cell Therapy for Acute Myeloid Leukemia

    Sponsor: Radboud University Medical Center. Phase: PHASE1. Conditions: Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, Relapsed, Adult

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT06632652: Telenursing System by Providing Health Education and Lifestyle Modification Among Diabetic Patients in Bangladesh

    Sponsor: Hiroshima University. Phase: NA. Conditions: Diabetes Mellitus

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT05809752: A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV)

    Sponsor: H. Lee Moffitt Cancer Center and Research Institute. Phase: PHASE1. Conditions: Leptomeningeal Disease, Triple Negative Breast Cancer, HER2-positive Breast Cancer

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT01984138: REVIVE: Replens Versus Intra-Vaginal Estrogen for the Treatment of Vaginal Dryness on Aromatase Inhibitor Therapy

    Sponsor: Polly A. Niravath, MD. Phase: PHASE2. Conditions: Estrogen Receptor Positive Breast Cancer, Breast Cancer

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT04271358: Peer Coaching Intervention in Young Adults With Congenital Heart Disease

    Sponsor: Duke University. Phase: NA. Conditions: Congenital Heart Disease, Congenital Heart Defect

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT05933655: Re-thinking the Role of Peers And Training Patients [RePeAT]

    Sponsor: University of Rochester. Phase: NA. Conditions: Cardiovascular Diseases

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT05904548: Atrial Flutter Ablation in the iCMR

    Sponsor: Imricor Medical Systems. Phase: NA. Conditions: Atrial Flutter Typical

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT02638155: Food Addiction and Hormone Study

    Sponsor: Texas Tech University. Phase: . Conditions: Disordered Eating

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT07543939: Peak Airway Pressure and Respiratory Mechanics During PRVC Ventilation in Laparoscopic Surgery

    Sponsor: Specialized Medical Center (SMC). Phase: . Conditions: Intraoperative Ventilation, Respiratory Mechanics

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07252739: KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)

    Sponsor: Merck Sharp & Dohme LLC. Phase: PHASE2. Conditions: Malignant Neoplasm

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07426757: An Open-Label Study to Evaluate PF-07994525 in Participants With Advanced Cancers

    Sponsor: Pfizer. Phase: PHASE1. Conditions: Advanced Malignancies, Advanced Cancer

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT06165601: Proteinuria in Renal Transplant Patients Treated With Dapagliflozin

    Sponsor: University Hospital, Montpellier. Phase: NA. Conditions: Chronic Kidney Diseases

    full page →ctgov ↗
    ›WITHHELDphase readoutNCT06546501: [Trial of device that is not approved or cleared by the U.S. FDA]

    Sponsor: [Redacted]. Phase: . Conditions:

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT05876312: Safety, Tolerability, PK and PD of ADX-038 in Healthy Participants and Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients

    Sponsor: ADARx Pharmaceuticals, Inc.. Phase: PHASE1. Conditions: Paroxysmal Nocturnal Hemoglobinuria (PNH)

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07569419: Proof of Principle Study for an Efficacy Trial of Linaclotide for Cystic Fibrosis

    Sponsor: University of Nottingham. Phase: EARLY_PHASE1. Conditions: Cystic Fibrosis (CF)

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT06965465: A Study to Learn How Different Amounts of the Study Medicine Called PF-07999415 Are Tolerated and Act in the Body in Healthy Adults

    Sponsor: Pfizer. Phase: PHASE1. Conditions: Healthy

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT05023967: Metformin and Nightly Fasting in Women With Early Breast Cancer

    Sponsor: M.D. Anderson Cancer Center. Phase: PHASE2. Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT07618507: Resistance Profile to Antiretroviral Medications in Individuals Living With HIV Who Failed a First-Line Regimen With Tenofovir / Lamivudina and Dolutegravir in Brasil

    Sponsor: Federal University of São Paulo. Phase: NA. Conditions: HIV, HIV -1 Infection

    full page →ctgov ↗
    ›TERMINATEDphase readoutNCT03968107: Diagnostic Performance of Antenatal Ultrasound for High-Risk Intestinal Malrotation

    Sponsor: University Hospital, Montpellier. Phase: . Conditions: Pregnancy Related

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07413692: BTL-699-2 and HPM-6000UF Devices for the Improvement of Depressive Symptoms and Urinary Incontinence in Postpartum and Early Post-Childbirth Women

    Sponsor: BTL Industries Ltd.. Phase: NA. Conditions: Depressive Symptoms, Urinary Incontinence

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT05461092: Regional Nerve Blocks to Improve Analgesia and Recovery in Older Adults Undergoing Spinal Fusion

    Sponsor: University of Iowa. Phase: EARLY_PHASE1. Conditions: Delirium, Pain, Back, Spinal Fusion, Thoracolumbar Interfascial Plane Block

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT07505836: Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 12-23 Months

    Sponsor: Sinovac Biotech Co., Ltd. Phase: PHASE3. Conditions: Epidemic Meningitis, Meningococcal Vaccines

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07382336: A Mobile Application for Early Detection and Symptoms Trajectories of Postpartum Depression Using Ecological Momentary Assessment (EMA)

    Sponsor: The Hong Kong Polytechnic University. Phase: . Conditions: Postpartum Depression (PPD)

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07605936: Frailty in Older Adults With Prostate Cancer: a Prospective Cohort Study

    Sponsor: University of Limerick. Phase: . Conditions: Frailty at Older Adults, Prostate Cancer

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07244211: MAPT Protocol: Fixation Versus Arthroplasty Surgical Treatments for Early Recovery After HIP Fracture (FASTER-HIP)

    Sponsor: University of Southern California. Phase: NA. Conditions: Femoral Neck Fractures

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT04633811: Effect of Weight Loss on Urinary Oxalate Excretion in Obese Calcium Oxalate Kidney Stone Formers

    Sponsor: University of Alabama at Birmingham. Phase: NA. Conditions: Kidney Stone

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07197944: Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS

    Sponsor: Zealand Pharma. Phase: PHASE3. Conditions: Short Bowel Syndrome

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT06894849: Text -Based Depression Screening Among Cancer Survivors

    Sponsor: Medical University of South Carolina. Phase: NA. Conditions: Cancer, Depression Secondary to Other Disease, Cancer Survivor

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT06045338: Mind Body Intervention for Long COVID-19

    Sponsor: Beth Israel Deaconess Medical Center. Phase: NA. Conditions: Long COVID, Post-Acute Sequelae of COVID-19, COVID Long-Haul

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT07494058: A Study of Home vs Hospital Treatment in People With Fabry, Gaucher or Hunter Conditions in Mexico

    Sponsor: Takeda. Phase: . Conditions: Lysosomal Disease

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT03253848: Simplified Patient Care Strategy in Decreasing Early Death in Patients With Acute Promyelocytic Leukemia

    Sponsor: ECOG-ACRIN Cancer Research Group. Phase: NA. Conditions: Acute Promyelocytic Leukemia With PML-RARA, t(15;17)

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07394855: Mechanisms of Persistent Fatigue

    Sponsor: University Hospital, Akershus. Phase: . Conditions: Fatigue Post Viral

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT07249658: Effects of Power and High-Intensity Gait Training for Functional Mobility an Ambulation in Chronic Stroke

    Sponsor: Riphah International University. Phase: NA. Conditions: Stroke

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT06508658: A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

    Sponsor: Genmab. Phase: PHASE3. Conditions: Diffuse Large B-Cell Lymphoma

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07257055: Phase 2 Study of BTKi-Rituximab Induction Followed by Glofitamab Consolidation in High Risk Untreated MCL Patients - WINDOW-4 Study

    Sponsor: M.D. Anderson Cancer Center. Phase: PHASE2. Conditions: Phase 2 Study, MCL, BTKi, Rituximab, Glofitamab

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT03315455: Efficacy, Safety, and Pharmacokinetic Study of Prophylactic Emicizumab Versus No Prophylaxis in Hemophilia A Participants

    Sponsor: Hoffmann-La Roche. Phase: PHASE3. Conditions: Hemophilia A

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT06047548: A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

    Sponsor: Eli Lilly and Company. Phase: PHASE3. Conditions: Overweight, Obesity

    full page →ctgov ↗
    ›ENROLLING_BY_INVITATIONphase readoutNCT06285448: Feasibility of Lecanemab Registry and Clinical Outcome Measures

    Sponsor: HealthPartners Institute. Phase: . Conditions: Alzheimer Disease

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT06507748: A Study to Evaluate the Feasibility of a Physiologic Biomarker to Assess Pain and Other Sensory Problems Using Pupillometry in Participants With Neurofibromatosis Type 1 (NF1)

    Sponsor: National Cancer Institute (NCI). Phase: NA. Conditions: Neurofibromatosis Type 1

    full page →ctgov ↗
    ›ENROLLING_BY_INVITATIONphase readoutNCT06720948: The ION Facet Screw System Ambispective Evaluation

    Sponsor: SurGenTec LLC. Phase: . Conditions: Intra-facet ION 3D Facet Screw System

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT04365855: The Olmsted NAFLD Epidemiology Study (TONES)

    Sponsor: Mayo Clinic. Phase: NA. Conditions: Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT03787355: Clinical Evaluation of Vertical Inter-implant Papilla Height in Platform Matched Implants in Comparison to Morse Connection Abutments

    Sponsor: Cairo University. Phase: NA. Conditions: Interimplant Mucosa

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT05821855: A Study to Evaluate Adverse Events and Change in Disease Activity With the XEN45 Glaucoma Treatment System Implantation In Adult Participants With Open-Angle Glaucoma in China

    Sponsor: AbbVie. Phase: PHASE4. Conditions: Open-angle Glaucoma, OAG

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT04184648: Comparison of Classification Standards of Bronchopulmonary Dysplasia (BPD) in Premature Infants

    Sponsor: Wang Jianhui. Phase: . Conditions: Bronchopulmonary Dysplasia

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT07630948: Adherence and Safety of Ribociclib Plus Aromatase Inhibitors in Patients With Early Stage, HR+ and HER2- Breast Cancer

    Sponsor: Institute of Oncology Ljubljana. Phase: PHASE4. Conditions: Breast Cancer, Adherence, Medication

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT07595848: Integration of Wearable Sensor Devices Into a Single System to Predict the Onset of Sepsis

    Sponsor: Check Point R & D Ltd. Phase: NA. Conditions: Sepsis

    full page →ctgov ↗
    ← prev
    page 56 of 98
    next →